The world is changing at an unprecedented pace. Intensifying climate change, rising geopolitical risks and widening healthcare disparities are creating increasingly complex social challenges. These directly and indirectly affect the stable supply of medicines, access to healthcare, and the daily lives of the patients we serve. For the company, these changes represent both risks and opportunities to create value.

Amid such changes, our responsibility as a healthcare company has never been greater. What must we do to continue contributing not only to patients today, but future generations of patients?
This question lies at the heart of our approach to sustainability.

The company identifies and assesses risks and opportunities arising from changes in the external environment and reflects the findings in our five-year business plan, covering FY2026 to FY2030. At the core of this process is the delivery of value to patients — through oncology medicines and other therapies. Our products and R&D pipeline represent the very hope of patients living with disease. Contributing to the treatment of cancer and other illnesses, improving prognosis, and maintaining and enhancing quality of life through innovative pharmaceuticals are the cornerstones of our business.
To ensure the sustained delivery of this value to society, we have established "Be a trusted partner for sustainable society" as a core strategic pillar. Guided by this commitment, we are addressing six priority areas fully integrated with our business activities:
-Fostering a patient-centric corporate culture
-Conducting business with high ethical standards
-Developing and strengthening our talent
-Further enhancing our corporate culture and working environment
-Enforcing rigorous compliance
-Reducing our environmental impact

We believe that through these efforts — mitigating business risks, strengthening our competitiveness, and contributing to addressing social challenges — we simultaneously build trust among our diverse stakeholders.
As one example, we are working to reduce our environmental footprint across the entire value chain. These efforts enhance our resilience to future climate-related risks and enable us to respond swiftly to disruptions in medicine supply and shifts in disease patterns — ultimately strengthening our business continuity and ensuring more sustainable value delivery to patients and their families.
Finally, building trust requires more than action alone — it also requires stakeholder engagement and transparency. The company is committed to credible disclosure that ensures our initiatives and their progress are properly understood and evaluated. We also engage with diverse stakeholders to understand their expectations and concerns, continuously validate the relevance of our efforts, and incorporate the outcomes into our management decision-making. Through this process, we enhance the transparency and consistency of our initiatives, building trust-based relationships with our stakeholders. We are convinced that this cumulative effort will underpin the long-term sustainability of our business.